Why clinical trial budgets fail at the negotiation table

A clinical trial budget is not a price list. It is the financial translation of a protocol. When a negotiation drags on for months, the cause is usually that the first draft never captured what the protocol actually asks a site to do.

Here are the gaps we see most often, on both sides of the table, and what to do about each one.

1. The budget was not built from the schedule of assessments

The schedule of assessments is the only reliable source for what a study costs. Every visit, every procedure, every questionnaire and every sample has a cost in staff time, equipment and overhead. A budget built from a previous study of a similar phase will always miss something, because protocols differ in exactly the details that consume site time.

Build the grid procedure by procedure. Price each line. Then total the visit. A site can accept a number it can trace back to the work; it cannot accept a number that appeared from nowhere.

What this looks like in practice

• One row per visit, one column per procedure, with the protocol's own visit names.
• Screening and rescreening priced separately, because they consume real time whether or not the patient enrols.
• Unscheduled and early termination visits priced in advance, rather than negotiated during the study.

2. Invoiceable items are treated as an afterthought

Per-visit payments are only part of a study's money. The items billed outside the visit grid are where value quietly disappears. These typically include screen failures, unscheduled visits, protocol amendments, record storage, pharmacy and laboratory fees, IRB or ethics fees, equipment and shipping costs, and staff time for monitoring visits and queries.

If these are not listed and priced in the budget, they become a negotiation during the study, at the worst possible moment: when the work is already done and the site is out of pocket.

3. Pass-through costs are not separated from site fees

Pass-through costs are reimbursements, not income. Mixing them into the per-patient figure makes the budget look generous while leaving the site to fund third parties from its own margin. Keep them in their own schedule, with a stated process for evidencing them, and both parties can see the real economics of the study.

4. Payment terms are left vague

A fair budget with poor payment terms is still a problem for a site. Terms deserve the same attention as the numbers:

• Payment frequency. Monthly and quarterly cycles behave very differently for a site's cash flow.
• Trigger for payment. Data entered, data monitored, or invoice received are three different things, sometimes months apart.
• Holdback. The percentage, and precisely what releases it, should be written down. An unspecified holdback tends to remain unpaid.
• Startup fee. Sites carry cost before the first patient. A startup payment reduces the strain and is standard practice.

5. Fair market value is asserted rather than evidenced

Both sides benefit from documented benchmarking. Sponsors need defensible pricing for compliance reasons. Sites need to know that an offer reflects the market rather than an internal target. When the reasoning behind a number is shared, the discussion shifts from position to evidence, and it moves faster.

6. Nobody owns the negotiation

Budgets often move between a study manager, a legal reviewer and a finance team, none of whom owns the outcome. Redlines sit in inboxes, and the site chases. Assigning one owner, with an approved range and clear escalation rules, does more for the timeline than any template.

What a well drafted budget prevents

• Months of counteroffers before a site can activate and enrol.
• Amendments raised purely to correct pricing that should have been right at the start.
• Site frustration, which quietly affects recruitment and data quality.
• Accruals that never match reality, because the budget and the payments were never aligned.

Getting the first draft right is not about being generous or firm. It is about being accurate. An accurate budget is easier for the other side to accept, and far easier to reconcile once the study is running.

Talk to us about your study if you would like this handled for you, or read more about our sponsor services and research site services.